Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

PURPOSE OF REVIEW: The newer, higher-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS)—orals and monoclonals—have more profound immunomodulatory and immunosuppressive properties than the older, injectable therapies and require risk mitigation strategies to reduce the risk of se...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Tyler Ellis, Kister, Ilya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Neurology of Systemic Diseases (J. Biller, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132488/
https://www.ncbi.nlm.nih.gov/pubmed/34009478
http://dx.doi.org/10.1007/s11910-021-01117-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132488/
https://www.ncbi.nlm.nih.gov/pubmed/34009478
http://dx.doi.org/10.1007/s11910-021-01117-y

Ejemplares similares